# Effect of Comorbidities on Inflammatory Bowel Disease-Related Colorectal Cancer: A Nationwide Inpatient Review

Arnold N. Forlemu, Raissa Nana Sede Mbakop, Shehroz Aslam, Zaid Ansari, Indu Srinivasan, Keng-Yu Chuang

<figure><img src="image_1.png" /></figure>

## ► To cite this version:

Arnold N. Forlemu, Raissa Nana Sede Mbakop, Shehroz Aslam, Zaid Ansari, Indu Srinivasan, et al.. Effect of Comorbidities on Inflammatory Bowel Disease-Related Colorectal Cancer: A Nationwide Inpatient Review. Cureus Journal of Medical Science, 2022, 14 (8), pp.e27599. 10.7759/cureus.27599. hal-03890347

HAL Id: hal-03890347

https://hal.science/hal-03890347

Submitted on 8 Dec 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_2.png" /></figure>
Review began 07/10/2022

Review ended 08/02/2022

Published 08/02/2022

© Copyright 2022

Forlemu et al. This is an open access
article distributed under the terms of the
Creative Commons Attribution License CC-
BY 4.0., which permits unrestricted use,
distribution, and reproduction in any
medium, provided the original author and
source are credited.

# Effect of Comorbidities on Inflammatory Bowel Disease-Related Colorectal Cancer: A Nationwide Inpatient Review

Arnold N. Forlemu¹, Raissa Nana Sede Mbakop²,³, Shehroz Aslam⁴, Zaid Ansari⁴, Indu Srinivasan⁴, Keng-Yu Chuang⁴

1. Internal Medicine/Gastroenterology and Hepatology, University of Nebraska Medical Center, Omaha, USA 2. Gastroenterology, Universite De Rennes 1, Rennes, FRA 3. Internal Medicine, Piedmont Athens Regional, Athens, USA 4. Internal Medicine/Gastroenterology, Creighton University School of Medicine, Phoenix, USA

Corresponding author: Arnold N. Forlemu, arnold.forlemu@ndus.edu

Abstract

Introduction

The risk of inflammatory bowel disease-associated colorectal cancer (IBD-CRC) is known to increase with primary sclerosing cholangitis (PSC) and a family history of CRC. However, the impact of comorbidities such as liver disease, obesity, diabetes, chronic lung, heart, and renal disease, and psychiatric illness on the risk of IBD-CRC remains unclear. We evaluated the effect of these comorbidities on the risk of IBD-CRC.

Methods

A retrospective review from 2009 to 2014 was conducted using the National Inpatient Sample data for adults 18 years and older. Patients with IBD (360,892), of whom 2,831 had CRC were identified using the International Classification of Diseases, Ninth Revision codes (ICD-9). Data on comorbidities were also obtained. Adjusted odds ratios (aOR) and confidence intervals (CI) were computed via logistic regression to evaluate the effect of comorbidities on the risk of IBD-CRC; the p-value was set at <0.05.

Results

The mean age of IBD patients in this study was 52.36±0.03. A majority of the patients with IBD-CRC were white and were significantly older compared to those without cancer (60 vs 52 years, p<0.05). The risk of colon cancer in IBD was increased by having a non-cholestatic liver disease (aOR 1.51, CI 1.23-1.86, p<0.01). Also, patients younger than 50 years with liver disease were at an increased risk of IBD-associated colon cancer in comparison to older patients (aOR 1.83 vs 1.34, p<0.05). Notably, diabetes, chronic pulmonary disease, renal failure, psychiatric illnesses, and rheumatoid diseases, were inversely associated with the risk of IBD-CRC (p<0.05). After stratifying by IBD subtypes, non-cholestatic liver disease was still independently associated with a higher risk for colon cancer in patients with ulcerative colitis or Crohn's disease (ulcerative colitis: aOR 1.43, CI 1.08-1.89; Crohn's disease: aOR 1.46, CI 1.10-2.00).

Conclusions

Patients with IBD who have non-cholestatic liver disease might have a higher risk for colon cancer, even at a younger age. These patients may require close colon cancer surveillance.

Categories: Internal Medicine, Gastroenterology, Oncology

Keywords: cancer surveillance, colorectal neoplasia, crohn's disease, ulcerative colitis, liver disease, comorbidities

Introduction

Inflammatory bowel disease-associated colorectal cancer (IBD-CRC) is a serious complication of inflammatory bowel disease (IBD); accounting for about 2% of all colorectal cancer (CRC), and 15% of all-cause mortality among IBD patients [1]. It is frequently diagnosed at an advanced cancer stage as early IBD-CRC detection has remained a clinical challenge [1]. The risk of IBD-CRC is known to increase with a family history of CRC, primary sclerosing cholangitis (PSC), disease duration, disease extension, and active intestinal inflammation [2,3]. However, the effect of comorbidities such as diabetes, obesity, chronic lung diseases, and liver disease on the risk of IBD-CRC remains unclear. A recent study in Canada by Loo et al. found respiratory diseases, chronic kidney disease, and diabetes to be associated with cancer in patients with IBD [4]. The direct association between frequent comorbidities and IBD-CRC risk in the US remains to be established. Given that IBD-CRC has a worse prognosis than sporadic CRC [1], early detection of IBD-CRC is paramount. It is necessary to identify comorbidities and risk factors that may raise awareness to warrant closer surveillance of IBD-CRC to help decrease morbidity and mortality associated with this condition. The purpose of this study was to evaluate the effect of comorbidities on the risk of IBD-CRC.
Materials And Methods

A retrospective review from 2009 to 2014 was conducted using the National Inpatient Sample (NIS) data to identify IBD patients diagnosed with CRC. The NIS is the largest publicly available all-payer inpatient database in the US with more than seven million hospital stays each year [5], as a part of the Healthcare Cost and Utilization Project (HCUP). It is designed to be nationally representative and captures a significant number of community hospitals in the US. The HCUP database contains de-identified data on nationwide hospital admissions including demographic information, clinical data, comorbidities, discharge diagnoses, procedures, outcomes, and hospitalization costs. The NIS database list patients with a primary discharge diagnosis and up to 29 secondary discharge diagnoses and 15 procedure codes. It lacks information on clinical details such as clinical stages of a disease, laboratory, and pharmacy data [5]. This study was approved by our institutional review board (IRB) and deemed exempt from IRB review due to the de-identified nature of HCUP data (IRB number 2021-031).

Study sample

Patients with IBD were identified using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for ulcerative colitis and Crohn's disease (556.x and 555.x), respectively. Patients with ulcerative colitis (UC) and Crohn's disease (CD) were then grouped to constitute IBD patients. Likewise, patients with CRC within the IBD patient population were identified with ICD-9-CM codes 153.x and 154.x. (Table 1).

<table><caption>TABLE 1: ICD-9-CM diagnostic codes and AHRQ comorbidity groups</caption><thead><tr><td>Description</td><td>ICD-9-CM code/AHRQ comorbidity groups</td></tr></thead><tbody><tr><td>Ulcerative colitis (556.x)</td><td>556.0, 556.1, 556.2, 556.3, 556.4, 556.5, 556.6, 556.8, 556.9</td></tr><tr><td>Crohn's disease (555.x)</td><td>555.0, 555.1, 555.2, 555.9</td></tr><tr><td>Colorectal cancer (153.x and 154.x)</td><td>153.0, 153.1, 153.2, 153.3, 153.4, 153.6, 153.7, 153.8, 153.9, 154.0, 154.1</td></tr><tr><td>Dyslipidemia (272.x)</td><td>272.0, 272.1, 272.2, 272.3, 272.4</td></tr><tr><td>Hypothyroidism</td><td>243-244.2, 244.8, 244.9</td></tr><tr><td>Obesity</td><td>278.0, 278.00, 278.01, 278.03, 649.10-649.14, 793.91, V85.30-V85.39, V85.41-V85.45, V85.54</td></tr><tr><td>Liver disease</td><td>Chronic non-cholestatic liver disease: hepatitis (B, C, alcohol, fatty liver), liver cirrhosis</td></tr><tr><td>Pulmonary embolism and complications</td><td>Pulmonary embolism with and without infarcts (septic, saddle, iatrogenic, chronic), pulmonary hypertension, chronic pulmonary heart disease</td></tr><tr><td>Diabetes</td><td>Uncomplicated and complicated diabetes</td></tr><tr><td>Renal failure</td><td>Chronic kidney disease (III, IV, V, endstage), renal dialysis</td></tr><tr><td>Hypertension</td><td>Uncomplicated and complicated hypertension</td></tr><tr><td>Chronic pulmonary disease</td><td>Bronchitis/emphysema, chronic pulmonary obstructive disease, asthma, bronchiectasis, interstitial lung disease</td></tr><tr><td>Congestive heart failure</td><td>Congestive heart failure (rheumatic, systolic, diastolic, combined, acute, chronic, acute on chronic)</td></tr><tr><td>Rheumatoid diseases</td><td>Scleroderma, systemic lupus erythematosus, sicca syndrome, rheumatoid arthritis, polymyositis, dermatomyositis, ankylosing spondylitis, polymyalgia rheumatica, connective tissue disorders</td></tr><tr><td>Psychoses</td><td>Schizophrenia, manic disorders, psychosis, paranoid</td></tr><tr><td>Depression</td><td>Depressive disorders excluding ones with psychoses</td></tr></tbody></table>

ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification codes, AHRQ: Agency for Healthcare Research and Quality

We analyzed CRC as a whole, and as rectal and colon cancers individually to reflect some evidence suggesting that sporadic colon and rectal cancers may behave differently in terms of carcinogenesis,
pathology, surgical topography, treatment modalities, and outcomes [6]; and these cancers may also behave differently in inflammation-related CRC. Rectosigmoid junction cancers were excluded during the individual analyses of colon and rectal cancers to minimize misclassification. All participants included in this study were aged 18 years or older.

## Covariates

Demographic information including age, gender, race/ethnicity, primary payer information (Medicare, Medicaid, private insurance, self-pay, other insurance), teaching status, and hospital location (rural vs urban), were obtained. Data on obesity, diabetes, renal failure, chronic respiratory disease, liver disease, congestive heart failure (CHF), pulmonary embolism (PE) and complications, dyslipidemia, depression, hypothyroidism, psychoses, and rheumatoid diseases were also obtained. Comorbidity measures in HCUP were assigned using the Elixhauser Agency for Healthcare Research and Quality (AHRQ) comorbidity software (Healthcare Cost and Utilization Project (HCUP), Rockville, MD, USA) which identifies coexisting medical conditions not directly related to the principal diagnosis and therefore likely to have originated prior to the hospital stay [7]. Each comorbidity may comprise more than one etiology of disease in an organ system as seen above in Table 1. We excluded 5,395 cases of CHF, hypertension, and renal failure to minimize misclassification because some of their ICD codes assigned by the AHRQ comorbidity software were shared. Likewise, we excluded patients with PSC, cholangitis or cholestatic disease, transplant liver disease, and biliary cirrhosis from the analysis to minimize confounding. Primary sclerosing cholangitis is a known risk factor for IBD-CRC, and ICD-9-codes for PSC include codes for other cholangitic and biliary conditions, hence they were excluded. Also, PSC is one of the primary reasons for liver transplantation in IBD patients, hence liver transplant patients with IBD likely also had PSC. Patients with hepatopulmonary syndrome and IBD were excluded due to very few cases.

## Outcomes of interest

We analyzed the following outcomes: 1) prevalence of comorbidities associated with CRC, colon cancer (CC), and rectal cancer (RC) in IBD patients; 2) adjusted odds ratios (OR) of comorbidities associated with CRC, CC, and RC in IBD patients; 3) adjusted ORs of comorbidities associated with CRC, CC, and RC in IBD stratified by UC and CD patients.

## Statistical analysis

Data were analyzed using Statistical Package for Social Sciences (SPSS) version 24.0 (IBM Corp., Armonk, NY, USA). The data are presented as weighted frequencies for categorical variables and as mean ± standard error for continuous variables. Chi-square statistics were used to compare proportions for categorical variables and Student's t-test was used to compare means for continuous variables. A univariate analysis was first conducted for the main effects to identify factors that were potentially associated with CRC in IBD patients. Logistic regression was then used to obtain adjusted estimates for comorbidities associated with CRC, CC, and RC in patients with IBD. Statistical significance was set at a two-tailed p<0.05 for all tests. Estimates were presented as odds ratios (ORs) and 95% confidence intervals (CI).

## Results

### Baseline characteristics

The number of inpatient admissions with a principal diagnosis of UC and CD totaled 360,892, of which 2,831 cases had IBD-CRC, 1,884 cases had IBD-CC, and 723 had IBD-RC. Of the IBD-CRC cases, 1,426 were identified in UC patients and 1,405 in CD patients. The mean age of IBD patients in this study was 52.36±0.03 (Table 2).

<table><thead><tr><th>Characteristic</th><th>IBD, N=360,892</th><th>Ulcerative colitis, N=132,035 (36.6%)</th><th>Crohn's disease, N=228,857 (63.8%)</th></tr></thead><tbody><tr><td>Age (in years) Mean±SE</td><td>52.36±0.03</td><td>55.54±0.06</td><td>50.52±18.0.04</td></tr><tr><td>Age (in years)</td><td></td><td></td><td></td></tr><tr><td>18-35</td><td>86,813 (24.1%)</td><td>27,519 (20.8%)</td><td>59,294 (25.9%)</td></tr><tr><td>35-50</td><td>82,139 (22.8%)</td><td>25,046 (19.0%)</td><td>57,093 (24.9%)</td></tr><tr><td>51-65</td><td>90,701 (25.1%)</td><td>32,673 (24.7%)</td><td>58,028 (25.4%)</td></tr><tr><td>>65</td><td>101,239 (28.1%)</td><td>46,797 (35.4%)</td><td>54,442 (23.8%)</td></tr><tr><td>Sex</td><td></td><td></td><td></td></tr><tr><td>Women</td><td>206,384 (57.2%)</td><td>71,079 (53.8%)</td><td>135,305 (59.1%)</td></tr><tr><td>Men</td><td>154,396 (42.8%)</td><td>60,898 (46.1%)</td><td>93,498 (40.9%)</td></tr></tbody></table>
Race

<table><tr><td>White</td><td>262,474 (72.9%)</td><td>94,916 (71.9%)</td><td>167,558 (73.2%)</td></tr><tr><td>Black</td><td>34,645 (9.6%)</td><td>11,173 (8.5%)</td><td>23,472 (10.3%)</td></tr><tr><td>Hispanic</td><td>17,591 (4.9%)</td><td>8,814 (6.7%)</td><td>8,777 (3.8%)</td></tr><tr><td>Asian/Pacific islander</td><td>3269 (0.9%)</td><td>1,715 (1.3%)</td><td>1,554 (0.7%)</td></tr><tr><td>Native American</td><td>1334 (0.4%)</td><td>473 (0.4%)</td><td>861 (0.4%)</td></tr><tr><td>Other</td><td>7872 (2.2%)</td><td>3,399 (2.6%)</td><td>4,473 (2.0%)</td></tr></table>

Payment method

<table><tr><td>Medicare</td><td>141,066 (39.1%)</td><td>54,323 (41.1%)</td><td>86,743 (37.9%)</td></tr><tr><td>Medicaid</td><td>43,394 (12.0%)</td><td>12,718 (9.6%)</td><td>30,676 (13.4%)</td></tr><tr><td>Private insurance</td><td>143,700 (39.8%)</td><td>53,631 (40.6%)</td><td>90,077 (39.4%)</td></tr><tr><td>Self-pay</td><td>18,352 (5.1%)</td><td>6,015 (4.6%)</td><td>12,337 (5.4%)</td></tr><tr><td>Other insurance</td><td>2064 (0.6%)</td><td>673 (0.5%)</td><td>1,391 (0.6%)</td></tr></table>

Hospital type

<table><tr><td>Urban</td><td>101,524 (28.1%)</td><td>38,317 (29.0%)</td><td>63,207 (27.6%)</td></tr><tr><td>Rural</td><td>19,245 (5.3%)</td><td>6,476 (4.9%)</td><td>12,769 (5.6%)</td></tr></table>

Teaching status

<table><caption>TABLE 2: Baseline characteristics of IBD patients</caption><tr><td>Non-teaching hospital</td><td>81</td><td>38</td><td>43</td></tr><tr><td>Teaching hospital</td><td>34</td><td>16</td><td>18</td></tr><tr><td>Colorectal cancer</td><td>2831 (0.8%)</td><td>1,426 (1.1%)</td><td>1,405 (0.6%)</td></tr><tr><td>Colon cancer</td><td>1884 (0.5%)</td><td>933 (0.7%)</td><td>951 (0.4%)</td></tr><tr><td>Rectal cancer</td><td>723 (0.2%)</td><td>365 (0.3%)</td><td>358 (0.2%)</td></tr><tr><td>Rheumatoid diseases</td><td>107,028 (4.7%)</td><td>5,622 (4.3%)</td><td>11,406 (5.0%)</td></tr><tr><td>Congestive heart failure</td><td>19,770 (5.5%)</td><td>8,622 (6.5%)</td><td>11,148 (4.9%)</td></tr><tr><td>Chronic pulmonary disease</td><td>61,911 (17.2%)</td><td>21,985 (16.7%)</td><td>39,926 (17.4%)</td></tr><tr><td>Diabetes</td><td>55,541 (5.2%)</td><td>23,391 (17.7%)</td><td>32,150 (14.0%)</td></tr><tr><td>Hypertension</td><td>134,859 (37.4%)</td><td>54,037 (40.9%)</td><td>80,822 (35.3%)</td></tr><tr><td>Hypothyroidism</td><td>36,822 (10.2%)</td><td>14,637 (11.1%)</td><td>22,185 (9.7%)</td></tr><tr><td>Chronic liver disease</td><td>14,411 (4.0%)</td><td>6,251 (4.7%)</td><td>8,160 (3.6%)</td></tr><tr><td>Obesity</td><td>29,535 (8.2%)</td><td>11,290 (8.6%)</td><td>18,245 (8.0%)</td></tr><tr><td>Chronic PE</td><td>6345 (1.8%)</td><td>2,852 (2.2%)</td><td>3,493 (1.5%)</td></tr><tr><td>Renal failure</td><td>29,506 (8.2%)</td><td>11,416 (8.6%)</td><td>18,090 (7.9%)</td></tr><tr><td>Dyslipidemia</td><td>68,380 (18.9%)</td><td>30,951 (23.4%)</td><td>37,429 (16.4%)</td></tr><tr><td>Depression</td><td>54,297 (15.0%)</td><td>17,583 (13.3%)</td><td>36,714 (16.0%)</td></tr><tr><td>Psychoses</td><td>18,932 (5.2%)</td><td>5,863 (4.4%)</td><td>13,069 (5.7%)</td></tr></table>

PE: Pulmonary embolism; Other race: Includes Asian/Pacific Islanders, Native American, and mixed races; mean±SE: mean±standard error; IBD: Inflammatory bowel disease
Risk factors and comorbidities in patients with IBD-CRC compared to IBD non-CRC patients

The prevalence of IBD-CRC was higher in men compared to women. Likewise, the majority of IBD-CRC patients were white and were significantly older compared to those without cancer (60 vs 52 years, p<0.05). Patients with IBD-CC had higher proportions of liver disease (5.6% vs 4.0%), and hypertension (40.8% vs 37.4%) compared to IBD non-CC patients, p<0.01 (Table 3).

<table><thead><tr><th rowspan="2">Parameter</th><th colspan="6">IBD (%)</th></tr><tr><th>CRC</th><th>Non-CRC</th><th>CC</th><th>Non-CC</th><th>RC</th><th>Non-RC</th></tr></thead><tbody><tr><td>Cancer types</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Age (years) Mean±SE</td><td>60.47±0.03</td><td>52.29±0.29*</td><td>61.37±0.37</td><td>52.31±0.03*</td><td>58.80±0.53</td><td>52.34±0.03<sup>a</sup></td></tr><tr><td>Age (years)<sup>a</sup></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>18 to 35</td><td>7.3</td><td>24.2</td><td>7.9</td><td>24.1</td><td>5.7</td><td>24.1</td></tr><tr><td>36 to 50</td><td>19.7</td><td>22.8</td><td>18.0</td><td>22.8</td><td>23.1</td><td>22.8</td></tr><tr><td>51 to 65</td><td>34.4</td><td>25.1</td><td>31.5</td><td>25.1</td><td>40.1</td><td>25.1</td></tr><tr><td>&gt;65</td><td>38.5</td><td>28.0</td><td>42.5</td><td>28.0</td><td>31.1</td><td>28.0</td></tr><tr><td>Sex<sup>a</sup></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Female</td><td>43.1</td><td>57.3</td><td>45.4</td><td>57.3</td><td>38.9</td><td>57.2</td></tr><tr><td>Male</td><td>56.9</td><td>42.7</td><td>54.6</td><td>42.7</td><td>61.1</td><td>42.8</td></tr><tr><td>Race</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>White</td><td>82.1</td><td>80.2</td><td>82.8</td><td>80.2</td><td>81.0</td><td>80.2</td></tr><tr><td>Black</td><td>7.2</td><td>10.6<sup>a</sup></td><td>6.6</td><td>10.6<sup>a</sup></td><td>9.3</td><td>10.6</td></tr><tr><td>Hispanic</td><td>6.0</td><td>5.4</td><td>6.0</td><td>5.4</td><td>5.7</td><td>5.4</td></tr><tr><td>Other</td><td>4.7</td><td>3.8</td><td>4.6</td><td>3.8</td><td>4.0</td><td>3.8</td></tr><tr><td>Payment methods<sup>a</sup></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Medicare</td><td>44.7</td><td>40.4</td><td>46.8</td><td>40.4</td><td>41.5</td><td>40.5</td></tr><tr><td>Medicaid</td><td>8.7</td><td>12.5</td><td>8.1</td><td>12.5</td><td>9.0</td><td>12.5</td></tr><tr><td>Private insurance</td><td>43.9</td><td>41.2</td><td>42.5</td><td>41.2</td><td>46.7</td><td>41.2</td></tr><tr><td>Self-pay</td><td>2.6</td><td>5.3</td><td>2.5</td><td>5.3</td><td>2.7</td><td>5.3</td></tr><tr><td>Other insurance</td><td>0.1</td><td>0.6</td><td>0.1</td><td>0.6</td><td>0.1</td><td>0.6</td></tr><tr><td>Hospital type</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Urban</td><td>82.7</td><td>84.1</td><td>81.3</td><td>84.1</td><td>85.2</td><td>84.1</td></tr><tr><td>Rural</td><td>17.3</td><td>15.9</td><td>18.7</td><td>15.9</td><td>14.8</td><td>15.9</td></tr><tr><td>Teaching status</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Non-teaching hospital</td><td>50.0</td><td>70.8</td><td>50.0</td><td>70.8</td><td></td><td>70.4</td></tr><tr><td>Teaching hospital</td><td>50.0</td><td>29.2</td><td>50.0</td><td>29.2</td><td></td><td>29.6</td></tr><tr><td>Rheumatoid diseases</td><td>2.3</td><td>4.7<sup>a</sup></td><td>2.4</td><td>4.7<sup>a</sup></td><td>1.9</td><td>4.7<sup>a</sup></td></tr><tr><td>Congestive heart failure</td><td>5.1</td><td>5.5</td><td>6.2</td><td>5.5</td><td>2.6</td><td>5.5<sup>a</sup></td></tr><tr><td>Chronic pulmonary disease</td><td>13.7</td><td>17.2<sup>a</sup></td><td>13.7</td><td>17.2<sup>a</sup></td><td>13.1</td><td>17.2<sup>a</sup></td></tr><tr><td>Diabetes</td><td>14.2</td><td>15.4</td><td>13.6</td><td>15.4<sup>a</sup></td><td>14.7</td><td>15.4</td></tr><tr><td>Hypertension</td><td>38.7</td><td>37.4</td><td>40.8</td><td>37.4<sup>a</sup></td><td>33.3</td><td>37.4<sup>a</sup></td></tr></tbody></table>
<table><caption>TABLE 3: Prevalence of comorbidities in IBD-CRC, IBD-CC, IBD-RC patients</caption><tr><td>Hypothyroidism</td><td>8.9</td><td>10.2<sup>a</sup></td><td>10.6</td><td>10.2</td><td>5.5</td><td>10.2<sup>a</sup></td></tr><tr><td>Chronic Liver disease</td><td>4.5</td><td>4.0</td><td>5.6</td><td>4.0<sup>a</sup></td><td>3.0</td><td>4.0</td></tr><tr><td>Obesity</td><td>7.0</td><td>8.2<sup>a</sup></td><td>7.1</td><td>8.2</td><td>6.6</td><td>8.2</td></tr><tr><td>Chronic PE</td><td>2.8</td><td>1.7<sup>a</sup></td><td>3.1</td><td>1.8<sup>a</sup></td><td>1.9</td><td>1.8</td></tr><tr><td>Renal failure</td><td>7.3</td><td>8.2</td><td>7.2</td><td>8.2</td><td>7.7</td><td>8.2</td></tr><tr><td>Dyslipidemia</td><td>18.8</td><td>18.9</td><td>20.4</td><td>18.9</td><td>14.8</td><td>19.0<sup>a</sup></td></tr><tr><td>Depression</td><td>9.9</td><td>15.1<sup>a</sup></td><td>9.7</td><td>15.1<sup>b</sup></td><td>11.3</td><td>15.1<sup>a</sup></td></tr><tr><td>Psychoses</td><td>2.6</td><td>5.3<sup>a</sup></td><td>2.6</td><td>5.3<sup>b</sup></td><td>2.5</td><td>5.3<sup>a</sup></td></tr></table>

PE: Pulmonary embolism; Other race: Includes Asian/Pacific Islanders, Native American, and mixed races; IBD: inflammatory bowel disease; CRC: colorectal cancer; CC: colon cancer; RC: rectal cancer; a: P<0.05; b: P<0.01

## Comorbidities independently associated with IBD-CRC

An increased risk of IBD-CC was seen in males (60%) of older ages and in those who had liver disease (OR 1.51, CI 1.23-1.86) and chronic PE (OR 1.64, CI 1.24-2.16). Also, patients <50 years old with liver disease were at an increased risk of IBD-CC in comparison to older patients (OR 1.83 vs 1.34, p<0.05). Although being obese was associated with an increased risk of IBD-CRC (OR 1.07, CI 0.92-1.26), IBD-CC (OR 1.05, CI 0.87-128), and IBD-RC (OR 1.16, CI 0.85-1.59), these associations were not statistically significant. Interestingly, hypertension, dyslipidemia, rheumatoid diseases, and psychoses were all inversely associated with the risk of IBD-CRC, IBD-CC, and IBD-RC in hospitalized patients (p<0.05) as shown in Figure 1, panels A, B, and C.
<figure><img src="image_3.png" /><figcaption>FIGURE 1: Factors associated with IBD-CRC, IBD-CC, IBD-RC patients</figcaption></figure>

Panel A: IBC-CRC findings, Panel B: IBD-CC findings, Panel C: IBD-RC findings, IBD: Inflammatory bowel disease, CRC: Colorectal cancer, CC: Colon cancer, RC: Rectal cancer, PE: Pulmonary embolism, OR: Adjusted odds ratio, LCL & UCL: Lower & upper-level confidence interval, Other race: includes Asian/Pacific Islanders, Native American, and mixed races

## Comorbidities associated with IBD-CRC patients stratified by ulcerative colitis and Crohn's disease

After stratifying data by type of IBD, male sex, age, chronic PE (in IBD-CRC and IBD-CC), and liver disease (in IBD-CC) were still independently associated with an increased risk of IBD-associated cancer in both UC and CD patients (p<0.05). Renal failure and dyslipidemia were inversely associated with IBD-CRC, IBD-CC, and IBD-RC risk only in UC patients (p<0.05). Likewise, rheumatoid diseases were significantly associated with a lower risk of IBD-CRC, IBD-CC, and IBD-RC only in CD patients. Chronic pulmonary disease, depression, and psychoses were associated with a lower risk of IBD-CRC and IBD-CC but not IBD-RC in both IBD subgroups (p<0.05). Hypertension and congestive heart failure were associated with a lower risk of IBD-RC but not IBD-CRC and IBD-CC in UC and CD subgroups (Figure 2 and Figure 3; panels A, B, and C).
<figure><img src="image_4.png" /><figcaption>FIGURE 2: Factors associated with IBD-CRC, IBD-CC, and IBD-RC patients stratified to ulcerative colitis</figcaption></figure>

Panel A: IBC-CRC findings, Panel B: IBD-CC findings, Panel C: IBD-RC findings, IBD: Inflammatory bowel disease, CRC: Colorectal cancer, CC: Colon cancer, RC: Rectal cancer, PE: Pulmonary embolism, OR: Adjusted odds ratio, LCL & UCL: Lower & upper-level confidence interval, Other race: Includes Asian/Pacific Islanders, Native American, and mixed races
<figure><img src="image_5.png" /><figcaption>FIGURE 3: Factors associated with IBD-CRC, IBD-CC, and IBD-RC patients stratified to Crohn's disease</figcaption></figure>

Panel A: IBC-CRC findings, Panel B: IBD-CC findings, Panel C: IBD-RC findings, IBD: Inflammatory bowel disease, CRC: Colorectal cancer, CC: Colon cancer, RC: Rectal cancer, PE: Pulmonary embolism, OR: Adjusted odds ratio, LCL & UCL: Lower & upper-level confidence interval, Other race: Includes Asian/Pacific Islanders, Native American, and mixed races

Discussion

Association between liver disease, pulmonary circulation disorders, obesity, and IBD-CRC

To the best of the authors' knowledge, this is the first nationwide study in the US to assess the impact of comorbidities on the risk of IBD-related colon and rectal cancers. This study found that patients with IBD and liver diseases had an increased risk of colon cancer. The risk was higher in younger patients compared to the older population (age >50). Liver disease was also associated with an increased risk of IBD-CRC, although this association was not statistically significant. Likewise, having a chronic PE was associated with an increased risk of IBD-CRC, and IBD-CC. Patients with liver disease and chronic PE who have IBD thus may warrant closer CRC surveillance. Additionally, routine counseling on risk modification in these patients,
such as smoking cessation, should be emphasized.

Patients with cholangitis and cholestatic disease were excluded from this study because IBD-CRC risk is well-established in diseases such as PSC [2,3]. Yet, the mechanism linking chronic non-cholestatic liver disease and IBD-CC was not clear. It has been suggested that the altered bile metabolism and inflammation associated with chronic liver disease might compound the proinflammatory state of IBD to increase the risk of IBD-CC, especially for the right-sided neoplasms [3,8]. Current guidelines recommend screening for colorectal cancer within one year of PSC diagnosis in a patient with IBD [5]. However, no guidelines exist currently to recommend CRC screening for IBD patients with chronic liver diseases such as hepatitis B or C and non-alcoholic steatohepatitis. Our findings suggest further research into this matter might be warranted.

Chronic PE in this study mostly represented PE with or without pulmonary infarcts and pulmonary hypertension. The risk of venous thromboembolism (VTE) in IBD patients is approximately three times that of the general population; the risk is also higher in hospitalized patients and patients with active disease [9]. Venous thromboembolism is more frequently seen in patients with active UC than in CD [10]. In our study, the percentage of hospitalized patients with chronic PE was higher in UC than in CD patients (2.2% vs 1.5%). As deep vein thrombosis (DVT)/PEs are frequently associated with malignancy, it is not surprising to find that chronic PE was positively associated with IBD-CRC in our study.

Although obesity is strongly associated with sporadic CRC [11], the link between obesity and IBD-associated CRC is largely unknown. Obesity appeared to be consistently associated with an increased risk of IBD-CRC in our study, however, these findings were not statistically significant. Similar to our study, Wu et al. (2019) who studied Chinese patients between 1999 and 2016 from eight tertiary-care hospitals noted no association between body mass index (BMI) and colonic neoplasia in IBD patients [12].

## Association between diabetes, chronic pulmonary disease, renal failure, rheumatoid diseases, and IBD-CRC

Diabetes in our study was associated with a lowered risk of IBD-CRC by 18%. Suggested theories for this observation include the following: 1) common comorbidities such as diabetes, hyperlipidemia, hypertension, and obesity are less common among patients with IBD [13]; 2) metformin, a widespread medication in diabetes management has been shown to decrease the incidence of CRC by interfering with CRC cell growth, proliferation, and angiogenesis leading to cell death [14]; 3) chronic lung diseases are frequently encountered with IBD. It has been postulated that certain medications used to treat IBD including sulfasalazine, 5-aminosalicylic acid, methotrexate, azathioprine, and infliximab can induce lung disease [15]. Inflammatory bowel disease increases the risk of all-cause mortality in patients with chronic lung diseases and these patients may not live long enough to develop CRC [16]. This may explain why fewer IBD patients with chronic pulmonary disease had CRC in our study.

Renal failure is rare in IBD patients and is often classified as an extraintestinal manifestation [17]. In agreement with our data, the prevalence of renal involvement in IBD is between 4% to 23% [17]. The decreased associated risk of IBD-CRC in renal failure patients in our study could be the result of increased early mortality in this patient population due to end-stage renal disease (ESRD) [18].

Rheumatoid diseases were inversely associated with the risk of IBD-CRC. This is consistent with previous studies [19]. One possible explanation for this observation is the increased use of cyclooxygenase-2 (COX-2)-selective inhibitors in this group of patients. These medications have consistently been associated with a decreased risk of CRC in the meta-analysis of observational and randomized controlled trials [20]. Thus, it is no surprise that such a protective effect on the risk of CRC would extend to IBD patients with rheumatoid diseases.

## Association between psychiatric disorders and IBD-CRC

The prevalence of psychiatric disorders (psychoses and depression) in IBD-CRC patients in our study was comparable to other published data [21-23] and was associated with a lower risk of IBD-CRC. Patients with IBD are known to have a high prevalence of mental illness leading to an increased risk of clinical relapse, disease severity, and surgery [22]. We suggest the following reasons for our findings: 1) patients with schizophrenia have been shown to express tumor suppressor genes and enhanced internal natural killer cell activities [23]; 2) patients with psychiatric illnesses might have an underestimated CRC rate due to less compliance to CRC screening and prevention procedures such as colonoscopies [25]; 3) many patients with depression are placed on selective serotonin reuptake inhibitors [24], which have been shown to reduce the risk of CRC; 4) patients with more severe IBD are most likely to develop depression and receive bowel resection such as colectomy if their diseases involve the colon. Through colectomy, their risk of developing CRC is significantly decreased [22].

## Association between hypertension, dyslipidemia, and IBD-CRC

In our study, patients with IBD and hypertension had a lower risk of IBD-CRC. This observation may be
related to the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in hypertensive patients. In effect, the use of ACEIs/ARBs is near ubiquitous in hypertensive patients and has been inversely associated with CRC risk due to their antifibrotic properties [25].

Likewise, dyslipidemia is also associated with a lower risk for IBD-CRC. Patients with IBD have shown low levels of low-density lipoprotein cholesterol (LDL) compared to healthy subjects [13]; possibly due to statin use which has also been shown to reduce the risk of CRC in IBD patients [26].

## Association between hypothyroidism, congestive heart failure, and IBD-CRC

We found an inverse association between hypothyroidism and IBD-CRC and IBD-RC patients. Similar to our study, L'Heureux et al. (2019) in Taiwan reported a 22% decrease in the risk association between hypothyroidism and CRC using a nationwide population-based cohort of 139,426 patients between 2008 to 2013 [27]. Thyroid hormone binding of cell surface receptor alpha-v-beta-3 (αVβ3) has been shown to lead to tumor cell proliferation and angiogenesis, and promotes viability in CRC cell lines [28]. Hence low levels of free thyroxine (T4) in hypothyroidism may protect against CRC by decreased interactions with these receptors.

Also, congestive heart failure in our study was inversely associated with the risk of IBD-CRC in both UC and CD patients. A possible explanation for this finding is that medications these patients often take including ACEIs/ARBs and statins may lower their cancer risk [25,26]. Our findings are contrary to those of Selvaraj et al. (2018) who did not find an association between heart failure and CRC in IBD patients [29]. However, their study was limited to men, and heart failure was determined by self-reporting without echocardiographic evidence.

## Clinical implications

The findings of the current study have important clinical implications. To the best of our knowledge, few studies to date have evaluated factors associated with IBD-CRC using a comprehensive list of comorbidities. Comorbid conditions cannot be overlooked in patients with IBD because their presence may significantly change medical practice strategies as well as the patient's prognosis [30]. This study may serve as a reference point for future studies to validate the impact of comorbidities on CRC risk in IBD patients at the population level. Also, colon cancer surveillance is both expensive and labor-intensive, and studies like ours done at the population level may enable practitioners to properly allocate resources to those IBD patients who have higher risk comorbidities.

## Strengths and limitations

This study used a nationwide database with a large sample size of patients seen over five years. Our study reflected real-world medical practice as we included multiple common comorbidities encountered in clinical practice. Our study did have some limitations. The NIS data is an inpatient-only database, and hence chronic medical conditions and procedures encountered mostly in the outpatient setting might be underrepresented. Also, as the NIS data does not contain information on disease duration, severity, as well as medication used by patients, their associations with CRC in IBD patients cannot be ascertained.

## Conclusions

Using a large, nationwide database, we found a positive association between non-cholestatic chronic liver disease and colon cancer IBD patients. The risk of colon cancer persisted in young IBD patients with non-cholestatic liver disease. On the other hand, IBD patients with comorbidities such as diabetes, chronic pulmonary diseases, hypertension, renal failure, psychiatric illnesses, dyslipidemia, and rheumatic diseases may have a negative association with CRC. Population based studies are required to further investigate the role of these comorbidities in IBD-CRC risk.

## Additional Information

### Disclosures

**Human subjects:** Consent was obtained or waived by all participants in this study. Valleywise Health IRB issued approval 2021-031. This study was approved by the Valleywise Health IRB and deemed exempt from IRB review due to the de-identified nature of the publicly available Healthcare Cost and Utilization Project (HCUP)/Nationwide Inpatient Sample (NIS) database. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
References

1. Zhen Y, Luo C, Zhang H: Early detection of ulcerative colitis-associated colorectal cancer. Gastroenterol Rep (Oxf). 2018, 6:83-92. 10.1093/gastro/goy010

2. Kim ER, Chang DK: Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis. World J Gastroenterol. 2014, 20:9872-9881. 10.3748/wjg.v20.i29.9872

3. Palmela C, Peerani F, Castaneda D, Torres J, Itzkowitz SH: Inflammatory bowel disease and primary sclerosing cholangitis: a review of the phenotype and associated specific features. Gut Liver. 2018, 12:17-29. 10.5009/gnl16510

4. Loo SY, Vutcovici M, Bitton A, Lakatos PL, Azoulay L, Suissa S, Brassard P: Risk of malignant cancers in inflammatory bowel disease. J Crohns Colitis. 2019, 13:1302-1310. 10.1093/ecco-jcc/jjz058

5. Steiner C, Elixhauser A, Schnaier J: The healthcare cost and utilization project: an overview. Eff Clin Pract. 2002, 5:143-151.

6. Paschke S, Jafarov S, Staib L, et al.: Are colon and rectal cancer two different tumor entities? A proposal to abandon the term colorectal cancer. Int J Mol Sci. 2018, 19:2577. 10.3390/ijms19092577

7. Elixhauser A, Steiner C, Harris DR, Coffey RM: Comorbidity measures for use with administrative data. Med Care. 1998, 36:8-27. 10.1097/00005650-199801000-00004

8. Francescone R, Hou V, Grivennikov SI: Cytokines, IBD, and colitis-associated cancer. Inflamm Bowel Dis. 2015, 21:409-418. 10.1097/MIB.00000000000000236

9. Andrade AR, Barros LL, Azevedo MF, Carlos AS, Damião AO, Sipahi AM, Leite AZ: Risk of thrombosis and mortality in inflammatory bowel disease. Clin Transl Gastroenterol. 2018, 9:142. 10.1038/s41424-018-0013-8

10. McCurdy JD, Kuenzig ME, Smith G, et al.: Risk of venous thromboembolism after hospital discharge in patients with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis. 2020, 26:1761-1768. 10.1093/ibd/izaa002

11. Aleksandrova K, Boeing H, Jenab M, et al.: Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res (Phila). 2011, 4:1873-1883. 10.1158/1940-6207.CAPR-11-0218

12. Wu XR, Zheng XB, Huang Y, et al.: Risk factors for colorectal neoplasia in patients with underlying inflammatory bowel disease: a multicenter study. Gastroenterol Rep (Oxf). 2019, 7:67-73. 10.1093/gastro/goy039

13. Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA: Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011, 106:741-747. 10.1038/ajg.2011.63

14. Chen CH, Lin CL, Hsu CY, Kao CH: Insulin enhances and metformin reduces risk of colorectal carcinoma in type-2 diabetes. QJM-INT J MED. 2020, 113:194-200. 10.1093/qjmed/hcz253

15. Parry SD, Barbatzas C, Peel ET, Barton JR: Sulphasalazine and lung toxicity. Eur Respir J. 2002, 19:756-764. 10.1183/09031936.02.00267402

16. Vutcovici M, Bitton A, Ernst P, Kezouh A, Suissa S, Brassard P: Inflammatory bowel disease and risk of mortality in COPD. Eur Respir J. 2016, 47:1357-1364. 10.1183/13993003.01945-2015

17. Ambruzs JM, Larsen CP: Renal manifestations of inflammatory bowel disease. Rheum Dis Clin North Am. 2018, 44:699-714. 10.1016/j.rdc.2018.06.007

18. Carlos CA, McCulloch CE, Hsu CY, et al.: Colon cancer screening among patients receiving dialysis in the united states: are we choosing wisely?. J Am Soc Nephrol. 2017, 28:2521-2528. 10.1681/ASN.2016091019

19. Huang WK, Chiou MJ, Kuo CF, Lin YC, Yu KH, See LC: No overall increased risk of cancer in patients with rheumatoid arthritis: a nationwide dynamic cohort study in Taiwan. Rheumatol Int. 2014, 34:1379-1386. 10.1007/s00296-014-2982-6

20. Rostom A, Dubé C, Lewin G, et al.: Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007, 146:376-389. 10.7326/0003-4819-146-5-200703060-00010

21. Zangenberg MS, El-Hussuna A: Psychiatric morbidity after surgery for inflammatory bowel disease: a systematic review. World J Gastroenterol. 2017, 23:8651-8659. 10.3748/wjg.v23.i48.8651

22. Moulton CD, Pavlidis P, Norton C, Norton S, Pariante C, Hayee B, Powell N: Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation?. Clin Exp Immunol. 2019, 197:308-318. 10.1111/cei.13276

23. Chou FH, Tsai KY, Su CY, Lee CC: The incidence and relative risk factors for developing cancer among patients with schizophrenia: a nine-year follow-up study. Schizophr Res. 2011, 129:97-103. 10.1016/j.schres.2011.02.018

24. Choi K, Chun J, Han K, et al.: Risk of anxiety and depression in patients with inflammatory bowel disease: a nationwide, population-based study. J Clin Med. 2019, 8:654. 10.3390/jcm8050654

25. Engineer DR, Burney BO, Hayes TG, Garcia JM: Exposure to ACEI/ARB and β-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer. Transl Oncol. 2013, 6:539-545. 10.1593/tlo.13346

26. Ananthakrishnan AN, Cagan A, Cai T, et al.: Statin use is associated with reduced risk of colorectal cancer in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016, 14:973-979. 10.1016/j.cgh.2016.02.017

27. L'Heureux A, Wieland DR, Weng CH, Chen YH, Lin CH, Lin TH, Weng CH: Association between thyroid disorders and colorectal cancer risk in adult patients in taiwan. JAMA Netw Open. 2019, 2:e193755. 10.1001/jamanetworkopen.2019.3755

28. Lee YS, Chin YT, Shih YJ, et al.: Thyroid hormone promotes β-catenin activation and cell proliferation in colorectal cancer. Horm Cancer. 2018, 9:156-165. 10.1007/s12672-018-0324-y

29. Selvaraj S, Bhatt DL, Claggett B, et al.: Lack of association between heart failure and incident cancer. J Am Coll Cardiol. 2018, 71:1501-1510. 10.1016/j.jacc.2018.01.069

30. Román AL, Muñoz F: Comorbidity in inflammatory bowel disease. World J Gastroenterol. 2011, 17:2723-
2733. 10.3748/wjg.v17.i22.2723